Abstract
Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent aggressive cancers in humans. Well-known risk factors include HPV infection, tobacco smoking, and alcohol consumption. HNSCC overall survival rate is one of the lowest among human malignancies. The poor prognosis of HNSCC often results from late-stage diagnosis, therapeutic resistance, high rates of recurrence, and frequent metastases to lymph nodes. To date, the TNM classification is still the best evaluation of disease progress; however, this method of staging does not pay attention to the molecular basis of tumorigenesis. An improvement in treatment efficacy and diagnostic capabilities will be realized through a better understanding of the pathogenesis and characteristics of HNSCC, a disease that has come to be characterized by confounding heterogeneity. This chapter is focused on molecular markers derived from key processes of cancerogenesis that are involved in metastasis, treatment resistance, avoidance of immune detection, inflammation, induction of angiogenesis, genome instability, dysregulation of cellular energetics, cell death, cancer stem cell biology, and rearrangement of tissues adjacent to the tumor. We will discuss biomarkers identified at different levels of cellular regulation (DNA, RNA, miRNA, and protein markers).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
Erenpreisa J, Cragg MS. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int. 2013;13:92. doi:10.1186/1475-2867-13-92.
Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–72. doi:10.1200/jco2005.04.8306.
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37. doi:10.1038/35052073.
Pedrero JMG, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al. Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 2005;114(2):242–8. doi:10.1002/ijc.20711.
Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009;45(4–5):324–34. doi:10.1016/j.oraloncology.2008.07.011.
Chang SE, Bhatia P, Johnson NW, Morgan PR, McCormick F, Young B, et al. RAS mutations in united-kingdom examples of oral malignancies are infrequent. Int J Cancer. 1991;48(3):409–12. doi:10.1002/ijc.2910480318.
White RA, Malkoski SP, Wang XJ. TGF beta signaling in head and neck squamous cell carcinoma. Oncogene. 2010;29(40):5437–46. doi:10.1038/onc.2010.306.
Saranath D, Chang SE, Bhoite LT, Panchal RG, Kerr IB, Mehta AR, et al. High-frequency mutation in codons 12 and 61 of h-RAS oncogene in chewing tobacco-related human oral-carcinoma in India. Br J Cancer. 1991;63(4):573–8. doi:10.1038/bjc.1991.133.
Lu SL, Herrington H, Reh D, Weber S, Bornstein S, Wang D, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 2006;20(10):1331–42. doi:10.1101/gad.1413306.
Grandis JR, Tweardy DJ. Elevated levels of transforming growth-factor-alpha and epidermal growth-factor receptor messenger-rna are early markers of carcinogenesis in head and neck-cancer. Cancer Res. 1993;53(15):3579–84.
Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824–32. doi:10.1093/jnci/90.11.824.
Ang KK, Berkey BA, Tu XY, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350–6.
Grandis JR, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 1998;4(1):13–20.
Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R, et al. Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol. 2014;50(3):168–77. doi:10.1016/j.oraloncology.2013.12.008.
Loeffler-Ragy J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer. 2006;42(1):109–11. doi:10.1016/j.ejca.2005.08.034.
Schwentner I, Witsch-Baumgartner M, Sprinzi GM, Krugmann J, Tzarl A, Jank S, et al. Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head Neck. 2008;30(8):1040–4. doi:10.1002/hed.20831.
Cassell A, Grandis JR. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2010;19(6):709–22. doi:10.1517/13543781003769844.
Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334:297–314.
Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 2003;63(11):2948–56.
Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res. 2006;66(24):11831–9. doi:10.1158/0008-5472.can-06-2876.
von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V, Groner B. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther. 2013;8(3):193–202.
Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012;26(7):641–50. doi:10.1101/gad.186965.112.
Limesand KH, Chibly AM, Fribley A. Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res. 2013;23(5):135–40. doi:10.1016/j.ghir.2013.06.001.
Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011;30(22):2504–13. doi:10.1038/onc.2010.622.
Patel V, Hood BL, Molinolo A, Lee NH, Conrads TP, Braisted JC, et al. Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res. 2008;14(4):1002–14. doi:10.1158/1078-0432.ccr-07-1497.
Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, et al. SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. Oral Oncol. 2012;48(11):1106–13. doi:10.1016/j.oraloncology.2012.05.014.
ten Klooster JP, von Leeuwen I, Scheres N, Anthony EC, Hordijk PL. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. Embo J. 2007;26(2):336–45. doi:10.1038/sj.emboj.7601518.
Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell. 2001;104(1):119–30. doi:10.1016/s0092-8674(01)00196-9.
Sobral LM, Sousa LO, Coletta RD, Cabral H, Greene LJ, Tajara EH, et al. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. Mol Cancer. 2014;13:32. doi:10.1186/1476-4598-13-32.
Ouchida AT, Uyemura VT, Leopoldino AM, Curti C. Potential SET protein involvement in autophagy in cancer. Faseb J. 2013;27.
Xi Y, Garshott DM, Brownell AL, Yoo GH, Lin HS, Freeburg TL, et al. Cantharidins induce ER stress and a terminal unfolded protein response in OSCC. J Dent Res. 2015;94(2):320–9. doi:10.1177/0022034514559376.
Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002;62(12):3351–5.
Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002;13(8):355–62.
Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A. 2000;97(8):4227–32. doi:10.1073/pnas.97.8.4227.
Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res. 2007;13(5):1362–6. doi:10.1158/1078-0432.ccr-06-2313.
Kannappan R, Yadav VR, Aggarwal BB. gamma-Tocotrienol but not gamma-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J Biol Chem. 2010;285(43):33520–8. doi:10.1074/jbc.M110.158378.
Sato J, Goto J, Murata T, Kitamori S, Yamazaki Y, Satoh A, et al. Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(3):330–6. doi:10.1016/j.tripleo.2010.03.040.
Chen Z, Malhotra PS, Thomas GR, Ondrey PG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999;5(6):1369–79.
Sato J, Ohuchi M, Abe K, Satoh T, Abe T, Yamazaki Y, et al. Correlation between salivary interleukin-6 levels and early locoregional recurrence in patients with oral squamous cell carcinoma: preliminary study. Head Neck. 2013;35(6):889–94. doi:10.1002/hed.23056.
Duffy SA, Taylor JMG, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113(4):750–7. doi:10.1002/cncr.23615.
Brailo V, Vucicevic-Boras V, Cekic-Arambasin A, Alajbeg IZ, Milenovic A, Lukac J. The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia. Oral Oncol. 2006;42(4):370–3. doi:10.1016/j.oraloncology.2005.09.001.
Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev. 2005;29(1):42–5. doi:10.1016/j.cdp.2004.10.003.
St John MAR, Li Y, Zhou XF, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130(8):929–35. doi:10.1001/archotol.130.8.929.
Chang KP, Kao HK, Wu CC, Fang KH, Chang YL, Huang YC, et al. Pretreatment interleukin-6 serum levels Are associated with patient survival for oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013;148(5):786–91. doi:10.1177/0194599813478573.
Zushi SI, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, Sugimachi M, et al. Stat3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer. 1998;78(3):326–30. doi:10.1002/(sici)1097-0215(19981029)78:3<326::aid-ijc12>3.0.co;2-4.
Lee TL, Yeh J, Van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther. 2006;5(1):8–19. doi:10.1158/1535-7163.mct-05-0069.
Allen MB, Zhang H, Ai L, Vural EA, Fan C. Promoter hypermethylation of SOCS1 gene, a negative regulator of EGFR-signaling pathway, significantly reduces the survival in patients with HNSCC. Lab Invest. 2014;94:314A–5.
Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 2005;24(44):6699–708. doi:10.1038/sj.onc.1208818.
Rossa Jr C, Sommer G, Spolidorio LC, Rosenzweig SA, Watson DK, Kirkwood KL. Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion. PLoS One. 2012;7(9):e45197. doi:10.1371/journal.pone.0045197.
Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10(1):51–7. doi:10.1038/nrc2772.
Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432(7015):307–15. doi:10.1038/nature03098.
Curry JM, Tuluc M, Whitaker-Menezes D, Ames JA, Anantharaman A, Butera A, et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle. 2013;12(9):1371–84. doi:10.4161/cc.24092.
Couture C, Raybaud-Diogene H, Tetu B, Bairati I, Murry D, Allard J, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94(3):713–22. doi:10.1002/cncr.10232.
Masood R, Hochstim C, Cervenka B, Zu S, Baniwal SK, Patel V, et al. A novel orthotopic mouse model of head and neck cancer and lymph node metastasis. Oncogenesis. 2013;2:e68. doi:10.1038/oncsis.2013.33.
Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009;15(22):6758–62. doi:10.1158/1078-0432.ccr-09-0784.
Vega-Pena A, Illades-Aguiar B, Flores-Alfaro E, Lopez-Bayghen E, Reyes-Maldonado E, Alarcon-Romero LD. Correlation between Ki-67 and telomerase expression with in situ hybridization for high-risk human papillomavirus. Arch Biol Sci. 2013;65(1):81–90. doi:10.2298/abs1301081p.
Lajer CB, Garns E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2012;106(9):1526–34. doi:10.1038/bjc.2012.109.
Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008;14(2):366–9. doi:10.1158/1078-0432.ccr-07-1402.
Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol. 2001;13(3):183–8. doi:10.1097/00001622-200105000-00009.
Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res. 2003;9(10):3635–40.
Koutsimpelas D, Pongsapich W, Heinrich U, Mann S, Mann WJ, Brieger J. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Oncol Rep. 2012;27(4):1135–41. doi:10.3892/or.2012.1624.
Yi B, Tan SX, Tang CE, Huang WG, Cheng AL, Li C, et al. Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J Cell Biochem. 2009;106(5):858–66. doi:10.1002/jcb.22051.
Jayasurya R, Sathyan KM, Lakshminarayanan K, Abraham T, Nalinakumari KR, Abraham EK, et al. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol. 2005;18(8):1056–66. doi:10.1038/modpathol.3800387.
Zolochevska O, Figueiredo ML. Expression of cell cycle regulator cdk2ap1 suppresses tumor cell phenotype by non-cell-autonomous mechanisms. Oral Oncol. 2009;45(9):E106–12. doi:10.1016/j.oraloncology.2009.05.001.
Matsuo K, Shintani S, Tsuji T, Nagata E, Lerman M, McBride J, et al. p12(DOC-1), a growth suppressor, associates with DNA polymerase alpha/primase. Faseb J. 2000;14(10):1318–24. doi:10.1096/fj.14.10.1318.
Kohno Y, Patel V, Kim Y, Tsuji T, Chin BR, Sun M, et al. Apoptosis, proliferation and p12(doc-1) profiles in normal, dysplastic and malignant squamous epithelium of the Syrian hamster cheek pouch model. Oral Oncol. 2002;38(3):274–80. doi:10.1016/s1368-8375(01)00055-0.
Figueiredo ML, Kim Y, St John MAR, Wong DTW. P12(CDK2-AP1) gene therapy strategy inhibits tumor growth in an in vivo mouse model of head and neck cancer. Clin Cancer Res. 2005;11(10):3939–48. doi:10.1158/1078-0432.ccr-04-2085.
Todd R, McBride J, Tsuji T, Donoff RB, Nagai M, Chou MY, et al. Deleted in oral cancer-1 (DOC-1), a novel oral tumor-suppressor gene. Faseb J. 1995;9(13):1362–70.
Shintani S, Mihara M, Terakado N, Nakahara Y, Matsumura T, Kohno Y, et al. Reduction of p12(DOC-1) expression is a negative prognostic indicator in patients with surgically resected oral squamous cell carcinoma. Clin Cancer Res. 2001;7(9):2776–82.
Bierie B, Moses HL. TGF beta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6(7):506–20. doi:10.1038/nrc1926.
Chaudhury A, Howe PH. The tale of transforming growth factor-beta (TGF beta) signaling: a soigne enigma. IUBMB Life. 2009;61(10):929–39. doi:10.1002/iub.239.
Lu SL, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, et al. Overexpression of transforming growth factor beta 1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 2004;64(13):4405–10. doi:10.1158/0008-5472.can-04-1032.
Engel ME, Datta PK, Moses HL. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J Cell Biochem. 1998;30–31:111–22.
Bian Y, Terse A, Du J, Hall B, Molinolo A, Zhang P, et al. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 2009;69(14):5918–26. doi:10.1158/0008-5472.can-08-4623.
Papadimitrakopoulou VA, Oh Y, El-Naggar A, Izzo J, Clayman G, Mao L. Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin Cancer Res. 1998;4(3):539–44.
Kim SK, Fan YH, Papadimitrakopoulou V, Clayman G, Hittelman WN, Hong WK, et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res. 1996;56(11):2519–21.
Takebayashi S, Ogawa T, Jung KY, Muallem A, Mineta H, Fisher SG, et al. Identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res. 2000;60(13):3397–403.
Bornstein S, White R, Malkoski S, Oka M, Han GW, Cleaver T, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest. 2009;119(11):3408–19. doi:10.1172/jci38854.
Wang D, Song HJ, Evans JA, Lang JC, Schuller DE, Weghorst CM. Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis. 1997;18(11):2285–90. doi:10.1093/carcin/18.11.2285.
Muro-Cacho CA, Anderson M, Cordero J, Munoz-Antonia T. Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma. Clin Cancer Res. 1999;5(6):1243–8.
Garrigueantar L, Munozantonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M. Missense mutations of the transforming growth-factor-beta type-II receptor in human head and neck squamous carcinoma-cells. Cancer Res. 1995;55(18):3982–7.
Fukai Y, Fukuchi M, Masuda N, Osawa H, Kato H, Nakajima T, et al. Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer. 2003;104(2):161–6. doi:10.1002/ijc.10929.
Chu TH, Yang CC, Liu CJ, Lui MT, Lin SC, Chang KW. miR-211 promotes the progression of head and neck carcinomas by targeting TGF beta RII. Cancer Lett. 2013;337(1):115–24. doi:10.1016/j.canlet.2013.05.032.
Kang SH, Bang YJ, Im YH, Yang HK, Lee DA, Lee HY, et al. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer. Oncogene. 1999;18(51):7280–6. doi:10.1038/sj.onc.1203146.
Chen TP, Yan W, Wells RG, Rimm DL, McNiff J, Leffell D, et al. Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases. Int J Cancer. 2001;93(5):653–61. doi:10.1002/ijc.1381.
Korc M. Smad4: gatekeeper gene in head and neck squamous cell carcinoma. J Clin Invest. 2009;119(11):3208–12. doi:10.1172/jci41230.
Qiu W, Schonleben F, Li XJ, Su GH. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett. 2007;245(1–2):163–70. doi:10.1016/j.canlet.2006.01.003.
Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 1999;18(39):5363–72. doi:10.1038/sj.onc.1202909.
Yu EA, Weaver DR. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. Aging US. 2011;3(5):479–93.
Yang X, Wood PA, Ansell CM, Quiton DFT, Oh E-Y, Du-Quiton J, et al. The circadian clock gene PER1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. 2009;26(7):1323–39. doi:10.3109/07420520903431301.
Fu LN, Pelicano H, Liu JS, Huang P, Lee CC. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111(1):41–50. doi:10.1016/s0092-8674(02)00961-3.
Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26(7):1241–6. doi:10.1093/carcin/bgi075.
Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 2014;13(20):3282–91. doi:10.4161/15384101.2014.954454.
Hu M-L, Yeh K-T, Lin P-M, Hsu C-M, Hsiao H-H, Liu Y-C, et al. Deregulated expression of circadian clock genes in gastric cancer. BMC Gastroenterol. 2014;14:67. doi:10.1186/1471-230x-14-67.
Chen Z, Liu P, Li C, Yong L, Chen I, Liang W, et al. Deregulated Expression of the Clock Genes in Gliomas. Technol Cancer Res Treat. 2013;12(1):91–7. doi:10.7785/tcrt.2012.500250.
Hsu C-M, Lin P-M, Lai C-C, Lin H-C, Lin S-F, Yang M-Y. PER1 and CLOCK: potential circulating biomarkers for head and neck squamous cell carcinoma. Head Neck. 2014;36(7):1018–26. doi:10.1002/hed.23402.
Hsu CM, Lin SF, Lu CT, Lin PM, Yang MY. Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumor Biol. 2012;33(1):149–55. doi:10.1007/s13277-011-0258-2.
Morrison H, Sherman LS, Legg J, Banine F, Isacke G, Haipek CA, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001;15(8):968–80. doi:10.1101/gad.189601.
Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000;14(13):1617–30.
McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 1998;12(8):1121–33. doi:10.1101/gad.12.8.1121.
Poli-Frederico RC, Bergamo NA, Reis PP, Kowalski LP, Zielenska M, Squire JA, et al. Chromosome 22q a frequent site of allele loss in head and neck carcinoma. Head Neck. 2000;22(6):585–90. doi:10.1002/1097-0347(200009)22:6<585::aid-hed7>3.0.co;2-4.
Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013;499(7458):346–9. doi:10.1038/nature12234. U122.
Tanabe KK, Nishi T, Saya H. Novel variants of CD44 arising from alternative splicing – changes in the CD44 alternative splicing pattern of MCF-7 breast-carcinoma cells treated with hyaluronidase. Mol Carcinog. 1993;7(4):212–20. doi:10.1002/mc.2940070403.
Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and-2. J Biol Chem. 2007;282(8):5597–607. doi:10.1074/jbc.M608358200.
Franzmann EJ, Reategui EP, Carraway KL, Hamilton KL, Weed DT, Goodwin WJ. Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(3):735–9. doi:10.1158/1055-9965.epi-04-0546.
Franzmann EJ, Reategui EP, Pereira LHM, Pedroso F, Joseph D, Allen GO, et al. Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck. 2012;34(5):687–95. doi:10.1002/hed.21810.
Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer. 2003;106(3):438–45. doi:10.1002/ijc.11252.
Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Pure E, et al. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol. 2007;176(4):535–44. doi:10.1083/jcb.200611058.
Pure E, Assoian RK. Rheostatic signaling by CD44 and hyaluronan. Cell Signal. 2009;21(5):651–5. doi:10.1016/j.cellsig.2009.01.024.
Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, et al. C-MET expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 2010;32(12):1655–64. doi:10.1002/hed.21383.
Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, Fang FM, et al. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 2009;28(30):2723–37. doi:10.1038/onc.2009.128.
Huang SF, Cheng SD, Chuang WY, Chen IH, Liao CT, Wang HM, et al. Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. World J Surg Oncol. 2012;10:40. doi:10.1186/1477-7819-10-40.
Hanken H, Grobe A, Cachovan G, Smeets R, Simon R, Sauter G, et al. CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin Oral Investig. 2014;18(1):269–76. doi:10.1007/s00784-013-0967-6.
Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M, Amornphimoltham P. Alterations of p53, pRb, cyclin D-1 and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol. 2000;36(4):334–9. doi:10.1016/s1368-8375(99)00093-7.
Uzawa N, Sonoda L, Myo K, Takahashi KI, Miyamoto R, Amagasa T. Fluorescence in situ hybridization for detecting genomic alterations of cyclin D1 and p16 in oral squamous cell carcinomas. Cancer. 2007;110(10):2230–9. doi:10.1002/cncr.23030.
Miyamoto R, Uzawa N, Nagaoka S, Hirata Y, Amagasa T. Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol. 2003;39(6):610–8. doi:10.1016/s1368-8375(03)00048-4.
Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D, et al. Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene. 2008;27(51):6607–22. doi:10.1038/onc.2008.251.
Lee KD, Lee HH, Joo HB, Lee HS, Yu TH, Chang HK, et al. Expression of MAGE A 1–6 mRNA in sputa of head and neck cancer patients – a preliminary report. Anticancer Res. 2006;26(2B):1513–8.
Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128–37. doi:10.1200/jco.2007.12.7662.
Suda T, Hama T, Kondo S, Yuza Y, Yoshikawa M, Urashima M, et al. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer. 2012;12:416. doi:10.1186/1471-2407-12-416.
Fenic I, Steger K, Gruber C, Arens C, Woenckhaus J. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep. 2007;18(1):253–9.
van Houten VMM, Tabor MP, van den Brekel MWM, Kummer JA, Denkers F, Dijkstra J, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol. 2002;198(4):476–86. doi:10.1002/path.1242.
van Houten VMM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MWM, et al. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res. 2004;10(11):3614–20. doi:10.1158/1078-0432.ccr-03-0631.
Lee JI, Soria JC, Hassan KA, El-Naggar AK, Tang X, Liu DD, et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg. 2001;127(12):1441–5.
Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress – head and neck cancer. N Engl J Med. 2001;345(26):1890–900. doi:10.1056/NEJMra001375.
Nevins JR. E2F – a link between the rb tumor suppressor protein and viral oncoproteins. Science. 1992;258(5081):424–9.
Pande P, Mathur M, Shukla NK, Ralhan R. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol. 1998;34(5):396–403.
Anagnostopoulos I, Hummel M. Epstein-Barr virus in tumours. Histopathology. 1996;29(4):297–315. doi:10.1111/j.1365-2559.1996.tb01414.x.
Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(5):1342–8. doi:10.1016/j.ijrobp.2007.02.012.
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–60. doi:10.1038/nrc2886.
Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–80. doi:10.1002/ijc.23173.
Wang F, Arun P, Friedman J, Chen Z, Van Waes C. Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol. 2009;9(4):389–95. doi:10.1016/j.coph.2009.06.005.
Le Bitoux MA, Stamenkovic I. Tumor-host interactions: the role of inflammation. Histochem Cell Biol. 2008;130(6):1079–90. doi:10.1007/s00418-008-0527-3.
Ruttkay-Nedecky B, Nejdl L, Gumulec J, Zitka O, Masarik M, Eckschlager T, et al. The role of metallothionein in oxidative stress. Int J Mol Sci. 2013;14(3):6044–66. doi:10.3390/ijms14036044.
Li XY, Chen HN, Epstein PN. Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J Biol Chem. 2004;279(1):765–71. doi:10.1074/jbc.M307907200.
Sato M, Bremner I. Oxygen free-radicals and metallothionein. Free Radic Biol Med. 1993;14(3):325–37. doi:10.1016/0891-5849(93)90029-t.
Ioachim E, Assimakopoulos D, Peschos D, Zissi A, Skevas A, Agnantis NJ. Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract. 1999;195(12):809–14.
Sochor J, Hynek D, Krejcova L, Fabrik I, Krizkova S, Gumulec J, et al. Study of metallothionein role in spinocellular carcinoma tissues of head and neck tumours using Brdicka reaction. Int J Electrochem Sci. 2012;7(3):2136–52.
Krejcova L, Fabrik I, Hynek D, Krizkova S, Gumulec J, Ryvolova M, et al. Metallothionein electrochemically determined using Brdicka reaction as a promising blood marker of head and neck malignant tumours. Int J Electrochem Sci. 2012;7(3):1767–84.
Dutsch-Wicherek M, Lazar A, Tomaszewska R, Kazmierczak W, Wicherek L. Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell carcinoma and its microenvironment. Cell Tissue Res. 2013;352(2):341–9. doi:10.1007/s00441-013-1566-1.
Gumulec J, Raudenska M, Adam V, Kizek R, Masarik M. Metallothionein – immunohistochemical cancer biomarker: a meta-analysis. PLoS One. 2014;9(1):e85346. doi:10.1371/journal.pone.0085346.
Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 2009;34(4):176–88. doi:10.1016/j.tibs.2008.12.008.
Walter V, Yin XY, Wilkerson MD, Cabanski CR, Zhao N, Du Y, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013;8(2):e56823. doi:10.1371/journal.pone.0056823.
Stacy DR, Ely K, Massion PP, Yarbrough WG, Hallahan DE, Sekhar KR, et al. Increased expression of nuclear factor E2 P45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck. 2006;28(9):813–8. doi:10.1002/hed.20430.
Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci. 2008;99(5):836–42. doi:10.1111/j.1349-7006.2008.00763.x.
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39(4):493–506. doi:10.1016/j.molcel.2010.07.023.
Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I, et al. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget. 2012;3(12):1641–52.
Chen Z, Yan B, Van Waes C. The role of the NF-kappaB transcriptome and proteome as biomarkers in human head and neck squamous cell carcinomas. Biomark Med. 2008;2(4):409–26. doi:10.2217/17520363.2.4.409.
Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck. 2007;29(10):959–71. doi:10.1002/hed.20615.
Zhang PL, Pellitteri PK, Law A, Gilroy PA, Wood GC, Kennedy TL, et al. Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol. 2005;18(7):924–32. doi:10.1038/modpathol.3800372.
Ondrey FG. Arachidonic acid metabolism: a primer for head and neck surgeons. Head Neck. 1998;20(4):334–49. doi:10.1002/(sici)1097-0347(199807)20:4<334::aid-hed9>3.0.co;2-#.
Tse GM, King AD, Yu AMC, Lam CCF, Chan AWH, Chen GG, et al. Correlation of biomarkers in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2010;143(6):795–800. doi:10.1016/j.otohns.2010.08.028.
Camacho M, Leon X, Fernandez-Figueras MT, Quer M, Vila L. Prostaglandin E-2 pathway in head and neck squamous cell carcinoma. Head Neck. 2008;30(9):1175–81. doi:10.1002/hed.20850.
Mauro A, Lipari L, Leone A, Tortorici S, Burruano F, Provenzano S, et al. Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in normal and pathological human oral mucosa. Folia Histochem Cytobiol. 2010;48(4):555–63. doi:10.2478/v10042-010-0066-3.
Shureiqi I, Lippman SA. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001;61(17):6307–12.
Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(5):991–4.
Sackett MK, Bairati I, Meyer F, Jobin E, Lussier S, Fortin A, et al. Prognostic significance of cyclooxygenase-2 overexpression in glottic cancer. Clin Cancer Res. 2008;14(1):67–73. doi:10.1158/1078-0432.ccr-07-2028.
Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer. 2013;4(1):66–83. doi:10.7150/jca.5112.
Cohen EG, Almahmeed T, Du BH, Golijanin D, Boyle JO, Soslow RA, et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res. 2003;9(9):3425–30.
Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33(7):708–14. doi:10.1053/hupa.2002.125376.
D-s S, M-q Z, Xia M, Li L, Y-h J. The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers. Med Oncol. 2012;29(2):707–13. doi:10.1007/s12032-011-9903-2.
Koontongkaew S, Monthanapisut P, Saensuk T. Inhibition of arachidonic acid metabolism decreases tumor cell invasion and matrix metalloproteinase expression. Prostaglandins Other Lipid Mediat. 2010;93(3–4):100–8. doi:10.1016/j.prostaglandins.2010.07.002.
Wang Y-H, Wu M-W, Yang A-K, Zhang W-D, Sun J, Liu T-R, et al. COX-2 gene increases tongue cancer cell proliferation and invasion through VEGF-C pathway. Med Oncol. 2011;28:S360–6. doi:10.1007/s12032-010-9737-3.
Ghirelli C, Hagemann T. Targeting immunosuppression for cancer therapy. J Clin Invest. 2013;123(6):2355–7. doi:10.1172/jci69999.
Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther. 2005;4(9):924–33.
Strome SE, Dong HD, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63(19):6501–5.
Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008;14(12):3706–15. doi:10.1158/1078-0432.ccr-07-5126.
Young MRI, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34(+) natural suppressor cells. Int J Cancer. 1997;74(1):69–74. doi:10.1002/(sici)1097-0215(19970220)74:1<69::aid-ijc12>3.0.co;2-d.
Chikamatsu K, Sakakura K, Whiteside TL, Furuya N. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2007;29(2):120–7. doi:10.1002/hed.20490.
Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4(+)CD25(+) cells educate CD4(+)D25(−)cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol. 2004;172(9):5213–21.
Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+ CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92(5):913–20. doi:10.1038/sj.bjc.6602407.
Millrud CR, Kvarnhammar AM, Uddman R, Bjornsson S, Riesbeck K, Cardell LO. The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival. PLoS One. 2012;7(12):e51120. doi:10.1371/journal.pone.0051120.
Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nat Rev Microbiol. 2005;3(1):59–69. doi:10.1038/nrmicro1066.
Wang S, Guo Z, Xia P, Liu T, Wang J, Li S, et al. Internalization of NK cells into tumor cells requires ezrin and leads to programmed cell-in-cell death. Cell Res. 2009;19(12):1350–62. doi:10.1038/cr.2009.114.
Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res. 2006;66(7):3629–38. doi:10.1158/0008-5472.can-05-3204.
Mhawech-Fauceglia P, Dulguerov P, Beck A, Bonet M, Allal AS. Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous cell carcinoma treated with radical radiotherapy. J Clin Pathol. 2007;60(2):185–9. doi:10.1136/jcp.2006.036624.
Xie L, Pries R, Kesselring R, Wulff S, Wollenberg B. Head and neck cancer triggers the internalization of TLR3 in natural killer cells. Int J Mol Med. 2007;20(4):493–9.
Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12(13):3890–5. doi:10.1158/1078-0432.ccr-05-2750.
Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006;66(18):9281–9. doi:10.1158/0008-5472.can-06-0488.
Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res. 2000;6(7):2794–802.
Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47(12):1148–53. doi:10.1016/j.oraloncology.2011.08.007.
Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010–20.
Young MRI. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck. 2006;28(5):462–70. doi:10.1002/hed.20331.
Johnson SD, De Costa AM, Young MR. Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer. Cancers (Basel). 2014;6(2):756–70. doi:10.3390/cancers6020756.
Jewett A, Head C, Cacalano NA. Emerging mechanisms of immunosuppression in oral cancers. J Dent Res. 2006;85(12):1061–73.
Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220–7. doi:10.1016/j.it.2010.04.002.
Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499–506. doi:10.4049/jimmunol.0802740.
Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev. 2006;213:213–27. doi:10.1111/j.1600-065X.2006.00437.x.
Bronte V, Chappell DB, Apolloni E, Cabrelle K, Wang M, Hwu P, et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8(+) T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999;162(10):5728–37.
Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H, Knecht R. Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck. 2007;29(3):244–8. doi:10.1002/hed.20503.
Liss C, Fekete MJ, Hasina R, Lam CD, Lingen MW. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer. 2001;93(6):781–5. doi:10.1002/ijc.1407.
Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6(5):1755–66.
Gabrilovich DI, Chen HL, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096–103. doi:10.1038/nm1096-1096.
Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003;63(19):6478–87.
Kaskas NM, Moore-Medlin T, McClure GB, Ekshyyan O, Vanchiere JA, Nathan CAO. Serum biomarkers in head and neck squamous cell cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(1):5–11. doi:10.1001/jamaoto.2013.5688.
Trellakis S, Bruderek K, Dumitru CA, Gholaman H, Gu X, Bankfalvi A, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer. 2011;129(9):2183–93. doi:10.1002/ijc.25892.
Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc. 2000;5(1):24–33. doi:10.1046/j.1087-0024.2000.00012.x.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.
Asakawa T, Esumi M, Endo S, Kida A, Ikeda M. Tongue cancer patients have a high frequency of allelic loss at the von Hippel-Lindau gene and other loci on 3p. Cancer. 2008;112(3):527–34. doi:10.1002/cncr.23200.
Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene. 2000;19(54):6297–305. doi:10.1038/sj.onc.1204012.
Le QT, Sutphin PD, Raychaudhuri S, Yu SCT, Terris DJ, Lin HS, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9(1):59–67.
Devoll RE, Li W, Woods KV, Pinero GJ, Butler WT, Farach-Carson MC, et al. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med. 1999;28(3):97–101.
Hong DY, Lee BJ, Lee JC, Choi JS, Wang SG, Ro JH. Expression of VEGF, HGF, IL-6, IL-8, MMP-9, telomerase in peripheral blood of patients with head and neck squamous cell carcinoma. Clin Exp Otorhinolaryngol. 2009;2(4):186–92. doi:10.3342/ceo.2009.2.4.186.
Jaiswal SG, Gadbail AR, Chaudhary MS, Jaiswal GR, Gawande M. Correlation of serum levels of vascular endothelial growth factor with TNM staging, histopathologic grading, and surgical therapy for oral squamous cell carcinoma. Quintessence Int. 2011;42(9):771–9.
Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000;18(10):2046–52.
Tse GM, Chan AWH, Yu KH, King AD, Wong KT, Chen GG, et al. Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol. 2007;14(12):3558–65. doi:10.1245/s10434-007-9632-0.
Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53(2):113–7. doi:10.1016/s0167-8140(99)00102-4.
Kyzas PA, Cunha IW, Ioannidis JPA. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11(4):1434–40. doi:10.1158/1078-0432.ccr-04-1870.
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27. doi:10.1200/jco.2005.06.081.
Jiang L, Zeng X, Yang H, Wang Z, Shen J, Bai J, et al. Oral cancer overexpressed 1 (ORAOV1): a regulator for the cell growth and tumor angiogenesis in oral squamous cell carcinoma. Int J Cancer. 2008;123(8):1779–86. doi:10.1002/ijc.23734.
Kashyap MK, Marimuthu A, Kishore CJH, Peri S, Keerthikumar S, Prasad TSK, et al. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther. 2009;8(1):36–46. doi:10.4161/cbt.8.1.7090.
Jin C, Jin Y, Gisselsson D, Wennerberg J, Wah TS, Stromback B, et al. Molecular cytogenetic characterization of the 11q13 amplicon in head and neck squamous cell carcinoma. Cytogenet Genome Res. 2006;115(2):99–106. doi:10.1159/000095228.
Czubayko F, Smith RV, Chung HC, Wellstein A. Tumor-growth and angiogenesis induced by a secreted binding-protein for fibroblast growth-factors. J Biol Chem. 1994;269(45):28243–8.
Czubayko F, LiaudetCoopman EDE, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997;3(10):1137–40. doi:10.1038/nm1097-1137.
Li W, Wang C, Juhn SK, Ondrey FG, Lin J. Expression of fibroblast growth factor binding protein in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009;135(9):896–901.
Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest. 2008;88(4):342–53. doi:10.1038/labinvest.2008.6.
Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6(5):327–34. doi:10.1038/cmi.2009.43.
Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003;3(3):219–31. doi:10.1016/s1535-6108(03)00030-8.
Xu B, Liu P, Li J, Lu H. c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation. Ann Oncol. 2010;21(3):670–2. doi:10.1093/annonc/mdp567.
Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9. doi:10.1016/j.ccr.2009.01.021.
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–31. doi:10.1016/j.ccr.2009.01.027.
Ebos JML, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007;104(43):17069–74. doi:10.1073/pnas.0708148104.
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442.
Ab Mutalib NS, Yoke-Kqueen C, Rahman SA, Sidik SM, Singh ASM, Learn-Han L. Differential microRNA expression and identification of putative miRNA targets and pathways in head and neck cancers. Int J Mol Med. 2011;28(3):327–36. doi:10.3892/ijmm.2011.714.
Cervigne NK, Reis PP, Machado J, Sadikovic B, Bradley G, Galloni NN, et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet. 2009;18(24):4818–29. doi:10.1093/hmg/ddp446.
Kozaki KI, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008;68(7):2094–105. doi:10.1158/0008-5472.can-07-5194.
Liu XQ, Chen ZG, Yu JS, Xia J, Zhou XF. MicroRNA Profiling and Head and Neck Cancer. Comparative and Functional Genomics. 2009;2009: 837514. doi:10.1155/2009/837514.
Liu J, Lei DP, Jin T, Zhao XN, Li GJ, Pan XL. Altered expression of miR-21 and PTEN in human laryngeal and hypopharyngeal squamous cell carcinomas. Asian Pac J Cancer Prev. 2011;12(10):2653–7.
Tu HF, Lin SC, Chang KW. MicroRNA aberrances in head and neck cancer: pathogenetic and clinical significance. Curr Opin Otolaryngol Head Neck Surg. 2013;21(2):104–11. doi:10.1097/MOO.0b013e32835e1d6e.
Chen LH, Tsai KL, Chen YW, Yu CC, Chang KW, Chiou SH, et al. MicroRNA as a novel modulator in head and neck squamous carcinoma. J Oncol. 2010;2010:135632. doi:10.1155/2010/135632.
Shiiba M, Uzawa K, Tanzawa H. MicroRNAs in head and neck squamous cell carcinoma (HNSCC) and oral squamous cell carcinoma (OSCC). Cancers (Basel). 2010;2(2):653–69. doi:10.3390/cancers2020653.
Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15(8):2850–5. doi:10.1158/1078-0432.ccr-08-3131.
Huret JL, Ahmad M, Arsaban M, Bernheim A, Cigna J, Desangles F, et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. Nucleic Acids Res. 2013;41(D1):D920–4. doi:10.1093/nar/gks1082.
Sparano A, Quesnelle KM, Kumar MS, Wang Y, Sylvester AJ, Feldman M, et al. Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. Laryngoscope. 2006;116(5):735–41. doi:10.1097/01.mlg.0000205141.54471.7f.
Scheckenbach K, Baldus SE, Balz V, Freund M, Pakropa P, Sproll C, et al. RAD51C – a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC). Oral Oncol. 2014;50(3):196–9. doi:10.1016/j.oraloncology.2013.11.007.
Yu HP, Zhang XY, Wang XL, Shi LY, Li YY, Li F, et al. DNA repair gene XRCC1 polymorphisms, smoking, and esophageal cancer risk. Cancer Detect Prev. 2004;28(3):194–9. doi:10.1016/j.cdp.2004.01.004.
Choudhury JH, Choudhury B, Kundu S, Ghosh SK. Combined effect of tobacco and DNA repair genes polymorphisms of XRCC1 and XRCC2 influence high risk of head and neck squamous cell carcinoma in northeast Indian population. Med Oncol. 2014;31(8):67. doi:10.1007/s12032-014-0067-8.
Vaezi A, Feldman CH, Niedernhofer LJ. ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer. Pharmgenomics Pers Med. 2011;4:47–63. doi:10.2147/pgpm.s20317.
Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene-product. Science. 1989;243(4893):934–7. doi:10.1126/science.2537532.
Hoadley KA, Fan C, Wilkerson MD, Mose LE, Jefferys SR, Auman JT, et al. Multi-tumor analysis of TCGA data identifies expression commonalities across tumor types. Cancer Res. 2013;73(8):SY12–03. doi:10.1158/1538-7445.am2013-sy12-03.
Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A. 2000;97(10):5462–7. doi:10.1073/pnas.97.10.5462.
Yen C-C, Chen Y-J, Pan C-C, Lu K-H, Chen PC-H, Hsia J-Y, et al. Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: TP63 is amplified in early carcinogenesis but down-regulated as disease progressed. World J Gastroenterol. 2005;11(9):1267–72.
Park BJ, Chiosea SI, Grandis JR. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark. 2011;9(1–6):325–39. doi:10.3233/cbm-2011-0163.
Pearlstein RP, Benninger MS, Carey TE, Zarbo RJ, Torres FX, Rybicki BA, et al. Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer. 1998;21(4):333–9. doi:10.1002/(sici)1098-2264(199804)21:4<333::aid-gcc7>3.0.co;2-#.
Kim MM, Califano JA. Molecular pathology of head-and-neck cancer. Int J Cancer. 2004;112(4):545–53. doi:10.1002/ijc.20379.
Tabor MP, Braakhuis BJM, van der Wal JE, van Diest PJ, Leemans CR, Brakenhoff RH, et al. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol. 2003;199(3):354–60. doi:10.1002/path.1285.
Califano J, vander Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res. 1996;56(11):2488–92.
Stadler ME, Patel MR, Couch ME, Hayes DN. Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am. 2008;22(6):1099–124. doi:10.1016/j.hoc.2008.08.007.
Jares P, Fernandez PL, Campo E, Nadal A, Bosch F, Aiza G, et al. PRAD-1 cyclin D1 gene amplification correlates with messenger-rna overexpression and tumor progression in human laryngeal carcinomas. Cancer Res. 1994;54(17):4813–7.
Callender T, Elnaggar AK, Lee MS, Frankenthaler R, Luna HA, Batsakis JG. PRAD-1 (CCND1) cyclin D1 oncogene amplification in primary head and neck squamous-cell carcinoma. Cancer. 1994;74(1):152–8. doi:10.1002/1097-0142(19940701)74:1<152::aid-cncr2820740124>3.0.co;2-k.
Lin MT, Morrison CD, Jones S, Mohamed N, Bucher J, Plass C. Copy number gain and oncogenic activity of YWHAZ/14-3-3 zeta in head and neck squamous cell carcinoma. Int J Cancer. 2009;125(3):603–11. doi:10.1002/ijc.24346.
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at P16/CDKN2 in primary human tumors. Nat Genet. 1995;11(2):210–2. doi:10.1038/ng1095-210.
Secades P, Rodrigo JP, Hermsen M, Alvarez C, Suarez C, Chiara MD. Increase in gene dosage is a mechanism of HIF-1 alpha constitutive expression in head and neck squamous cell carcinomas. Genes Chromosomes Cancer. 2009;48(5):441–54. doi:10.1002/gcc.20652.
Bauer VL, Braselmann H, Henke M, Mattern D, Walch A, Unger K, et al. Chromosomal changes characterize head and neck cancer with poor prognosis. J Mol Med JMM. 2008;86(12):1353–65. doi:10.1007/s00109-008-0397-0.
The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82. doi:10.1038/nature14129.
Lohavanichbutr P, Houck J, Fan W, Yueh B, Mendez E, Futran N, et al. Genome-wide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch Otolaryngol Head Neck Surg. 2009;135(2):180–8. doi:10.1001/archoto.2008.540.
Chung CH, Parker JS, Karaca G, Wu JY, Funkhouser WK, Moore D, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5(5):489–500. doi:10.1016/s1535-6108(04)00112-6.
Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010;5(1):e8960. doi:10.1371/journal.pone.0008960rr.
Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, et al. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract. Mod Pathol. 2013;26(1):117–24. doi:10.1038/modpathol.2012.139.
Roberson RS, Kussick SJ, Vallieres E, Chen SYJ, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005;65(7):2795–803. doi:10.1158/0008-5472.can-04-1270.
Wang Q, Wu PC, Roberson RS, Luk BV, Ivanova I, Chu E, et al. Survivin and escaping in therapy-induced cellular senescence. Int J Cancer. 2011;128(7):1546–58. doi:10.1002/ijc.25482.
Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6(8):611–22. doi:10.1038/nrg1656.
Zhang SZ, Dong MM, Teng XJ, Chen TH, Zhang S. Quantitative assay of telomerase activity in head and neck squamous cell carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2000;14(9):393–5.
Zhong LP, Chen GF, Xu ZF, Zhang X, Ping FY, Zhao SF. Detection of telomerase activity in saliva from oral squamous cell carcinoma patients. Int J Oral Maxillofac Surg. 2005;34(5):566–70. doi:10.1016/j.ijom.2004.10.007.
Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, et al. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res. 1996;56(24):5600–4.
Liao CT, Chang JTC, Wang HM, Chen IH, Lin CY, Chen TM, et al. Telomerase as an independent prognostic factor in head and neck squamous cell carcinoma. Head Neck. 2004;26(6):504–12. doi:10.1002/hed.20007.
Yamazaki H, Mori T, Yazawa M, Maeshima AM, Matsumoto F, Yoshi-moto S, et al. Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis. Lab Invest. 2013;93(12):1331–8. doi:10.1038/labinvest.2013.120.
Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One. 2011;6(1):e16466. doi:10.1371/journal.pone.0016466.
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106(33):13820–5. doi:10.1073/pnas.0905718106.
Zhang ZC, Sant’Ana M, Nor JE. The biology of head and neck cancer stem cells. Oral Oncol. 2012;48(1):1–9. doi:10.1016/j.oraloncology.2011.10.004.
Zhang P, Zhang Y, Mao L, Zhang Z, Chen W. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett. 2009;277(2):227–34. doi:10.1016/j.canlet.2008.12.015.
Chen Y-C, Chen Y-W, Hsu H-S, Tseng L-M, Huang P-I, Lu K-H, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385(3):307–13. doi:10.1016/j.bbrc.2009.05.048.
Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32(9):1195–201. doi:10.1002/hed.21315.
Kokko LL, Hurme S, Maula SM, Alanen K, Grenman R, Kinnunen I, et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 2011;47(6):510–6. doi:10.1016/j.oraloncology.2011.03.026.
Wang SJ, Wong G, de Heer AM, Xia WL, Bourguignon LYW. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope. 2009;119(8):1518–30. doi:10.1002/lary.20506.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104(3):973–8. doi:10.1073/pnas.0610117104.
Yuce I, Bayram A, Cagli S, Canoz O, Bayram S, Guney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol. 2011;32(2):141–6. doi:10.1016/j.amjoto.2010.01.001.
Lin JT, Chang TH, Chang CS, Wang WH, Su BW, Lee KD, et al. Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer. Oral Oncol. 2010;46(5):E29–33. doi:10.1016/j.oraloncology.2010.02.011.
Lee SH, Koo BS, Kim JM, Huang S, Rho YS, Bae WJ, et al. Wnt/beta-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4. J Pathol. 2014;234(1):99–107. doi:10.1002/path.4383.
Wu YJ, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127–34. doi:10.1089/scd.2008.0338.
Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett. 2010;289(2):151–60. doi:10.1016/j.canlet.2009.08.010.
Chu P-Y, Hu F-W, Yu C-C, Tsai L-L, Yu C-H, Wu B-C, et al. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer. Oral Oncol. 2013;49(1):34–41. doi:10.1016/j.oraloncology.2012.07.012.
Huang YC, Benaich N, Tape C, Kwok HF, Murphy G. Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation. Int J Biol Sci. 2014;10(7):702–14. doi:10.7150/ijbs.9326.
Kamarajan P, Shin JM, Qian X, Matte B, Zhu JY, Kapila YL. ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC. Cancer Med. 2013;2(6):793–802. doi:10.1002/cam4.147.
Chen YC, Chang CJ, Hsu HS, Chen YW, Tai LK, Tseng LM, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol. 2010;46(3):158–65. doi:10.1016/j.oraloncology.2009.11.007.
Chen H, Zhou L, Wan G, Dou T, Tian J. BMI1 promotes the progression of laryngeal squamous cell carcinoma. Oral Oncol. 2011;47(6):472–81. doi:10.1016/j.oraloncology.2011.03.016.
Lo WL, Yu CC, Chiou GY, Chen YW, Huang PI, Chien CS, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol. 2011;223(4):482–95. doi:10.1002/path.2826.
Sun S, Wang Z. Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer. 2011;129(10):2337–48. doi:10.1002/ijc.25927.
Wu MJ, Jan CI, Tsay YG, Yu YH, Huang CY, Lin SC, et al. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer. 2010;9:283. doi:10.1186/1476-4598-9-283.
von Rahden BH, Kircher S, Lazariotou M, Reiber C, Stuermer L, Otto C, et al. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett’s esophagus? J Exp Clin Cancer Res. 2011;30:23. doi:10.1186/1756-9966-30-23.
Raz R, Lee CK, Cannizzaro LA, D’Eustachio P, Levy DE. Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci U S A. 1999;96(6):2846–51. doi:10.1073/pnas.96.6.2846.
van Oosten AL, Costa Y, Smith A, Silva JCR. JAK/STAT3 signalling is sufficient and dominant over antagonistic cues for the establishment of naive pluripotency. Nat Commun. 2012;3:817. doi:10.1038/ncomms1822.
Lo J-F, Yu C-C, Chiou S-H, Huang C-Y, Jan C-I, Lin S-C, et al. The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers. Cancer Res. 2011;71(5):1912–23. doi:10.1158/0008-5472.can-10-2350.
Zhang X, Su L, Pirani AA, Wu HY, Zhang HZ, Shin DM, et al. Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis. 2006;23(3–4):209–22. doi:10.1007/s10585-006-9031-0.
Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112(12):1776–84. doi:10.1172/jci200320530.
Peinado HC, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004;48(5–6):365–75. doi:10.1387/ijdb.041794hp.
Medici D, Hay ED, Olsen BR. Snail and slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta 3. Mol Biol Cell. 2008;19(11):4875–87. doi:10.1091/mbc.E08-05-0506.
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1 alpha promotes metastasis. Nat Cell Biol. 2008;10(3):295–305. doi:10.1038/ncb1691.
Zhang JL, Cheng Q, Zhou Y, Wang Y, Chen XM. Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: correlations with poor prognosis. Oral Oncol. 2013;49(11):1043–50. doi:10.1016/j.oraloncology.2013.08.003.
Yu CC, Lo WL, Chen YW, Huang PI, Hsu HS, Tseng LM, et al. Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. J Oncol. 2011;2011. doi:10.1155/2011/609259.
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA 10b in breast cancer. Nature. 2007;449(7163):682–8. doi:10.1038/nature06174. U2.
Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, et al. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem. 2010;285(11):7986–94. doi:10.1074/jbc.M109.062877.
Chang KW, Liu CJ, Chu TH, Cheng HW, Hung PS, Hu WY, et al. Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. J Dent Res. 2008;87(11):1063–8.
Yang CC, Hung PS, Wang PW, Liu CJ, Chu TH, Cheng HW, et al. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathol Med. 2011;40(5):397–404. doi:10.1111/j.1600-0714.2010.01003.x.
Liu C-J, Tsai M-M, Hung P-S, Kao S-Y, Liu T-Y, Wu K-J, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010;70(4):1635–44. doi:10.1158/0008-5472.can-09-2291.
Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett. 2009;286(2):217–22. doi:10.1016/j.canlet.2009.05.030.
Jin Y, Chen D, Cabay RJ, Wang A, Crowe DL, Zhou X. Role of micro RNA-138 as a potential tumor suppressor in head and neck sqamous cell carcinoma. In: Jeon KW, editor. International review of cell and molecular biology, International review of cell and molecular biology, vol. 303. Amsterdam, Netherlands: Elsevier; 2013. p. 357–85. ISBN: 978-0-12-407697-6.
Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, et al. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer. 2010;127(3):505–12. doi:10.1002/ijc.25320.
Cai KM, Bao XL, Kong XH, Jinag W, Mao MR, Chu JS, et al. Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. Int J Mol Med. 2010;25(4):565–71. doi:10.3892/ijmm_00000378.
Benaich N, Woodhouse S, Goldie SJ, Mishra A, Quist SR, Watt FM. Rewiring of an epithelial differentiation factor, miR-203, to inhibit human squamous cell carcinoma metastasis. Cell Rep. 2014;9(1):104–17. doi:10.1016/j.celrep.2014.08.062.
Yu XY, Jiang XR, Li HX, Guo LP, Jiang W, Lu SH. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. Stem Cells Dev. 2014;23(6):576–85. doi:10.1089/scd.2013.0308.
Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(12):2804–14. doi:10.1002/ijc.25284.
Tamagawa S, Beder LB, Hotomi M, Gunduz M, Yata K, Grenman R, et al. Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med. 2014;33(4):879–86. doi:10.3892/ijmm.2014.1625.
Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2012;34(2):219–24. doi:10.1002/hed.21713.
Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15(17):5473–7. doi:10.1158/1078-0432.ccr-09-0736.
Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010;16(4):360–4. doi:10.1111/j.1601-0825.2009.01646.x.
Lu Y-C, Chen Y-J, Wang H-M, Tsai C-Y, Chen W-H, Huang Y-C, et al. Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res. 2012;5(4):665–74. doi:10.1158/1940-6207.capr-11-0358.
Lin S-C, Liu C-J, Lin J-A, Chiang W-F, Hung P-S, Chang K-W. miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis. Oral Oncol. 2010;46(3):204–8. doi:10.1016/j.oraloncology.2009.12.005.
Wong T-S, Liu X-B, Wong BY-H, Ng RW-M, Yuen AP-W, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008;14(9):2588–92. doi:10.1158/1078-0432.ccr-07-0666.
Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC, et al. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol. 2012;48(11):1114–9. doi:10.1016/j.oraloncology.2012.05.013.
Zhao D, Wang S-H, Feng Y, Hua C-G, Zhao J, Tang X-F. Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker. Hum Pathol. 2011;42(10):1514–23. doi:10.1016/j.humpath.2010.03.012.
Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappa B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006;66(16):8210–8. doi:10.1158/0008-5472.can-06-1213.
Yan M, Xu Q, Zhang P, Zhou XJ, Zhang ZY, Chen WT. Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma. BMC Cancer. 2010;10:437. doi:10.1186/1471-2407-10-437.
Hung KF, Lin SC, Liu CJ, Chang CS, Chang KW, Kao SY. The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med. 2003;32(8):461–7. doi:10.1034/j.1600-0714.2003.00185.x.
Ueda M, Shimada T, Goto Y, Tei K, Nakai S, Hisa Y, et al. Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. Auris Nasus Larynx. 2010;37(4):488–95. doi:10.1016/j.anl.2009.11.012.
Ou DL, Chien HF, Chen CL, Lin TC, Lin LI. Role of Twist in head and neck carcinoma with lymph node metastasis. Anticancer Res. 2008;28(2B):1355–9.
Shang ZJ, Liu K, Shao Z. Expression of chemokine receptor CCR7 is associated with cervical lymph node metastasis of oral squamous cell carcinoma. Oral Oncol. 2009;45(6):480–5. doi:10.1016/j.oraloncology.2008.06.005.
Li XG, Pan XL, Zhang H, Lei DP, Liu DY, Xu FL, et al. Overexpression of cFLIP in head and neck squamous cell carcinoma and its clinicopathologic correlations. J Cancer Res Clin Oncol. 2008;134(5):609–15. doi:10.1007/s00432-007-0325-7.
Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene. 2004;23(7):1439–47. doi:10.1038/sj.onc.1207258.
Yamada S, Yanamoto S, Kawasaki G, Mizuno A, Nemoto TK. Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma. Pathol Oncol Res. 2010;16(4):523–31. doi:10.1007/s12253-009-9245-y.
Rodrigo JP, Garcia-Carracedo D, Garcia LA, Menendez ST, Allonca E, Gonzalez MV, et al. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol. 2009;217(4):516–23. doi:10.1002/path.2462.
Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, et al. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br J Cancer. 2008;98(5):956–64. doi:10.1038/sj.bjc.6604245.
Gibcus JH, Mastik M, Menkema L, de Bock GH, Kluin PM, Schuuring E, et al. Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer. 2008;98(5):950–5. doi:10.1038/sj.bjc.6604246.
Tan CT, Chu CY, Lu YC, Chang CC, Lin BR, Wu HH, et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis. 2008;29(8):1519–27. doi:10.1093/carcin/bgn108.
Xu M, Li WY, Xu YH, Chen XM. Expression of CXCR4 in oral squamous cell carcinoma: correlations with clinicopathology and pivotal role of proliferation. J Oral Pathol Med. 2010;39(1):63–8. doi:10.1111/j.1600-0714.2009.00801.x.
Xu JK, Lu W, Zhang SL, Zhu CC, Ren TT, Zhu T, et al. Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma. Cancer Biol Ther. 2014;15(5):612–22. doi:10.4161/cbt.28181.
Patel V, Martin D, Malhotra R, Marsh CA, Doci CL, Veenstra TD, et al. DSG3 as a biomarker for the ultrasensitive detection of occult lymph node metastasis in oral cancer using nanostructured immunoarrays. Oral Oncol. 2013;49(2):93–101. doi:10.1016/j.oraloncology.2012.08.001.
Uehara M, Sano K, Ikeda H, Nonaka M, Asahina I. Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis. Oral Oncol. 2009;45(3):241–6. doi:10.1016/j.oraloncology.2008.05.007.
Kline ER, Muller S, Pan L, Tighiouart M, Chen Z, Marcus AI. Localization-specific LKB1 loss in head and neck squamous cell carcinoma metastasis. Head Neck. 2011;33(10):1501–12. doi:10.1002/hed.21638.
Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, et al. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer. 2010;126(11):2653–62. doi:10.1002/ijc.24948.
Yang MH, Chang SY, Chiou SH, Liu CJ, Chi CW, Chen PM, et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene. 2007;26(10):1459–67. doi:10.1038/sj.onc.1209929.
Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev. 2007;16(1):102–7. doi:10.1158/1055-9965.epi-06-0602.
Wang WL, Chang WL, Yeh YC, Lee CT, Chang CY, Lin JT, et al. Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract. Mol Carcinog. 2013;52(6):438–45. doi:10.1002/mc.21874.
Liu CJ, Chang KW, Lin SC, Cheng HW. Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma. Oral Oncol. 2009;45(10):920–5. doi:10.1016/j.oraloncology.2009.04.007.
Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H, Werner JA. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res. 2002;22(4):2221–7.
Hsu DSS, Chang SY, Liu CJ, Tzeng CH, Wu KJ, Kao JY, et al. Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity. Cancer Sci. 2010;101(4):1029–37. doi:10.1111/j.1349-7006.2009.01471.x.
Huang C, Huang K, Wang C, Jiang ZD, Li XX, Wang HP, et al. Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Oncol Rep. 2009;22(1):89–95.
Joo YH, Jung CK, Kim MS, Sun DI. Relationship between vascular endothelial growth factor and Notch1 expression and lymphatic metastasis in tongue cancer. Otolaryngol Head Neck Surg. 2009;140(4):512–8. doi:10.1016/j.otohns.2008.12.057.
Patel V, Rosenfeldt HM, Lyons R, Servitja JM, Bustelo XR, Siroff M, et al. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion. Carcinogenesis. 2007;28(6):1145–52. doi:10.1093/carcin/bgm008.
Kang SM, Elf S, Lythgoe K, Hitosugi T, Taunton J, Zhou W, et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest. 2010;120(4):1165–77. doi:10.1172/jci40582.
Muro-Cacho CA, Rosario-Ortiz K, Livingston S, Munoz-Antonia T. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2. Clin Cancer Res. 2001;7(6):1618–26.
Xie W, Bharathy S, Kim D, Haffty BG, Rimm DL, Reiss M. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res. 2003;14(2):61–73.
Kim YH, Kim SM, Kim YK, Hong SP, Kim MJ, Myoung H. Evaluation of survivin as a prognostic marker in oral squamous cell carcinoma. J Oral Pathol Med. 2010;39(5):368–75. doi:10.1111/j.1600-0714.2009.00844.x.
Lin JZ, Guan Z, Wang CA, Feng L, Zheng YQ, Caicedo E, et al. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappa B/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res. 2010;16(1):77–87. doi:10.1158/1078-0432.ccr-08-2362.
Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009;69(7):3105–13. doi:10.1158/0008-5472.can-08-3838.
O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92(3):556–68. doi:10.1002/1097-0142(20010801)92:3<556::aid-cncr1355>3.0.co;2-q.
Nohata N, Hanazawa T, Kinoshita T, Okamoto Y, Seki N. MicroRNAs function as tumor suppressors or oncogenes: aberrant expression of microRNAs in head and neck squamous cell carcinoma. Auris Nasus Larynx. 2013;40(2):143–9. doi:10.1016/j.anl.2012.07.001.
Lee TL, Yeh J, Friedman J, Yan B, Yang XP, Yeh NT, et al. A signal network involving coactivated NF-kappa B and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer. 2008;122(9):1987–98. doi:10.1002/ijc.23324.
Sun Q, Sakaida T, Yue W, Gollin SM, Yu J. Chemosensitization of head and neck cancer cells by PUMA. Mol Cancer Ther. 2007;6(12):3180–8. doi:10.1158/1535-7163.mct-07-0265.
Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer. 1999;85(1):164–70.
Chen S, Fribley A, Wang CY. Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-kappa B inhibitor. J Dent Res. 2002;81(2):98–102.
Yang F, Zeng QH, Yu GY, Li SL, Wang CY. Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal. 2006;18(5):679–87. doi:10.1016/j.cellsig.2005.06.015.
Li J, Huang H, Sun L, Yang M, Pan C, Chen W, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 2009;15(12):3998–4008. doi:10.1158/1078-0432.ccr-08-3053.
Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008;27(31):4373–9. doi:10.1038/onc.2008.72.
Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res. 2009;15(6):1915–22. doi:10.1158/1078-0432.ccr-08-2545.
Shi ZQ, Wang B, Chihanga T, Kennedy MA, Weber GF. Energy metabolism during anchorage-independence. Induction by osteopontin-c. PLoS One. 2014;9(8):e105675. doi:10.1371/journal.pone.0105675.
Tan K, Goldstein D, Crowe P, Yang JL. Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis. J Cancer Res Clin Oncol. 2013;139(11):1795–805. doi:10.1007/s00432-013-1482-5.
Xie TX, Zhou G, Zhao M, Sano D, Jasser SA, Brennan RG, et al. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. Laryngoscope. 2013;123(6):1416–23. doi:10.1002/lary.23846.
Campos MS, Neiva KG, Meyers KA, Krishnamurthy S, Nor JE. Endothelial derived factors inhibit anoikis of head and neck cancer stem cells. Oral Oncol. 2012;48(1):26–32. doi:10.1016/j.oraloncology.2011.09.010.
Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, et al. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res. 2012;18(20):5639–49. doi:10.1158/1078-0432.ccr-12-1213.
Buchheit CL, Weigel KJ, Schafer ZT. OPINION cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014;14(9):632–41. doi:10.1038/nrc3789.
Skvortsov S, Dudas J, Eichberger P, Witsch-Baumgartner M, Loeffler-Ragg J, Pritz C, et al. Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC). Br J Cancer. 2014;110(11):2677–87. doi:10.1038/bjc.2014.221.
Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42. doi:10.1016/j.cell.2007.12.018.
Vigneswaran N, Wu J, Song AR, Annapragada A, Zacharias W. Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp Mol Pathol. 2011;90(2):215–25. doi:10.1016/j.yexmp.2010.11.011.
Lozy F, Karantza V. Autophagy and cancer cell metabolism. Semin Cell Dev Biol. 2012;23(4):395–401. doi:10.1016/j.semcdb.2012.01.005.
Li CY, Johnson DE. Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. Cancer Lett. 2012;314(1):102–7. doi:10.1016/j.canlet.2011.09.020.
Zhu WY, Wang XH, Zhou Y, Wang HM. C2-ceramide induces cell death and protective autophagy in head and neck squamous cell carcinoma cells. Int J Mol Sci. 2014;15(2):3336–55. doi:10.3390/ijms15023336.
Schaaf MBE, Cojocari D, Keulers TG, Jutten B, Starmans MH, de Jong MC, et al. The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia. Radiother Oncol. 2013;108(3):529–34. doi:10.1016/j.radonc.2013.06.015.
Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol. 2013;15(7):741–50. doi:10.1038/ncb2757.
La Fleur L, Johansson A-C, Roberg K. A CD44(high)/EGFR(low) subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS One. 2012;7(9):e44071. doi:10.1371/journal.pone.0044071.
Ohnishi K, Ota I, Takahashi A, Yane K, Matsumoto H, Ohnishi T. Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck. Apoptosis. 2002;7(4):367–72. doi:10.1023/a:1016131614856.
Noutomi T, Chiba H, Itoh M, Toyota H, Mizuguchi J. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol. 2002;38(1):41–8. doi:10.1016/s1368-8375(00)00098-1.
Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer. 1999;84(6):573–9. doi:10.1002/(sici)1097-0215(19991222)84:6<573::aid-ijc6>3.0.co;2-r.
Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of Bcl-x(l) can confer a multidrug-resistance phenotype. Blood. 1995;86(5):1903–10.
Zhan QM, Alamo I, Yu K, Boise LH, Cherney B, Tosato G, et al. The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function. Oncogene. 1996;13(10):2287–93.
Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2009;15(5):1645–54. doi:10.1158/1078-0432.ccr-08-2581.
Hong L, Han Y, Zhang HW, Li MB, Gong TQ, Sun L, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010;251(6):1056–63. doi:10.1097/SLA.0b013e3181dd4ea9.
Toustrup K, Sorensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71(17):5923–31. doi:10.1158/0008-5472.can-11-1182.
Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010;116(9):2148–58. doi:10.1002/cncr.25009.
Zhang S, Mercado-Uribe I, Xing Z, Sun B, Kuang J, Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene. 2014;33(1):116–28. doi:10.1038/onc.2013.96.
Zhu GQ, Tang YL, Geng N, Zheng M, Jiang J, Li L, et al. HIF-alpha/MIF and NF-kappa B/IL-6 axes contribute to the recruitment of CD11b+ Gr-1+ myeloid cells in hypoxic microenvironment of HNSCC. Neoplasia. 2014;16(2):168–79. doi:10.1593/neo.132034.
Chiu TJ, Chen CH, Chien CY, Li SH, Tsai HT, Chen YJ. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Transl Med. 2011;9:31. doi:10.1186/1479-5876-9-31.
Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, et al. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer. 2013;109(8):2096–105. doi:10.1038/bjc.2013.576.
Dudas J, Schartinger VH, Romani A, Schweigl G, Kordsmeyer K, Marta PI, et al. Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. Tumor Biology. 2014;35(8):7807–19. doi:10.1007/s13277-014-2001-2.
Patel MR, Zhao N, Ang MK, Stadler ME, Fritchie K, Weissler MC, et al. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013;149(4):587–95. doi:10.1177/0194599813496522.
De Castro G, Pasini FS, Siqueira SAC, Ferraz AR, Villar RC, Snitcovsky IML, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep. 2011;25(3):693–9. doi:10.3892/or.2011.1133.
Togashi Y, Arao T, Kato H, Matsumoto K, Terashima M, Hayashi H, et al. Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production. Oncotarget. 2014;5(10):2962–73.
Sattler UGA, Meyer SS, Quennet V, Hoerner C, Knoerzer H, Fabian C, et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol. 2010;94(1):102–9. doi:10.1016/j.radonc.2009.11.007.
Tonigold M, Rossmann A, Meinold M, Bette M, Marken M, Henkenius K, et al. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. J Cancer Res Clin Oncol. 2014;140(10):1689–704. doi:10.1007/s00432-014-1727-y.
Liu W, Feng JQ, Shen XM, Wang HY, Liu Y, Zhou ZT. Two stem cell markers, ATP-binding cassette, G2 subfamily (ABCG2) and BMI-1, predict the transformation of oral leukoplakia to cancer. Cancer. 2012;118(6):1693–700. doi:10.1002/cncr.26483.
Grimm M, Krimmel M, Polligkeit J, Alexander D, Munz A, Kluba S, et al. ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma. Eur J Cancer. 2012;48(17):3186–97. doi:10.1016/j.ejca.2012.05.027.
Feng JQ, Mi JG, Wu L, Ma LW, Shi LJ, Yang X, et al. Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral cancer development. Oral Oncol. 2012;48(9):848–52. doi:10.1016/j.oraloncology.2012.03.015.
Castells M, Thibault B, Delord J-P, Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci. 2012;13(8):9545–71. doi:10.3390/ijms13089545.
Tripathi P, Kamarajan P, Somashekar BS, MacKinnon N, Chinnaiyan AM, Kapila YL, et al. Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A(2), a potential therapeutic target. Int J Biochem Cell Biol. 2012;44(11):1852–61. doi:10.1016/j.biocel.2012.06.025.
Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, et al. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer. 2011;117(13):2926–38. doi:10.1002/cncr.25868.
Li SJ, Yang XN, Wang P, Ran X. The effects of GLUT1 on the survival of head and neck squamous cell carcinoma. Cell Physiol Biochem. 2013;32(3):624–34. doi:10.1159/000354466.
Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, et al. Cancer cells metabolically “fertilize” the tumor microenvironment with hydrogen peroxide, driving the Warburg effect Implications for PET imaging of human tumors. Cell Cycle. 2011;10(15):2504–20. doi:10.4161/cc.10.15.16585.
Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol. 2010;6(1):127–48. doi:10.2217/fon.09.145.
Feron O. Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92(3):329–33. doi:10.1016/j.radonc.2009.06.025.
Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118(12):3930–42. doi:10.1172/jci36843.
Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol. 1997;150(2):409–15.
Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51(2):349–53. doi:10.1016/s0360-3016(01)01630-3.
Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J. 1999;343:281–99. doi:10.1042/0264-6021:3430281.
Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121(1):29–40. doi:10.1016/j.pharmthera.2008.09.005.
Brooks GA. Cell-cell and intracellular lactate shuttles. J Physiol London. 2009;587(23):5591–600. doi:10.1113/jphysiol.2009.178350.
Gladden LB. Lactate metabolism: a new paradigm for the third millennium. J Physiol London. 2004;558(1):5–30. doi:10.1113/jphysiol.2003.058701.
Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1 alpha-dependent mechanism. J Biol Chem. 2006;281(14):9030–7. doi:10.1074/jbc.M511397200.
Curry JM, Sprandio J, Cognetti D, Luginbuhl A, Bar-ad V, Pribitkin E, et al. Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol. 2014;41(2):217–34. doi:10.1053/j.seminoncol.2014.03.003.
Routray S, Sunkavali A, Bari KA. Carcinoma-associated fibroblasts, its implication in head and neck squamous cell carcinoma: a mini review. Oral Dis. 2014;20(3):246–53. doi:10.1111/odi.12107.
Lin SY, Dolfi SC, Amiri S, Li JD, Budak-Alpdogan T, Lee KC, et al. P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms. Int J Oncol. 2013;43(6):1817–23. doi:10.3892/ijo.2013.2109.
Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, et al. Stromal features are predictive of disease mortality in oral cancer patients. J Pathol. 2011;223(4):470–81. doi:10.1002/path.2830.
van Kempen LCL, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer. 2006;42(6):728–34. doi:10.1016/j.ejca.2006.01.004.
Erez N, Truitt M, Olson P, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappa B-dependent manner. Cancer Cell. 2010;17(2):135–47. doi:10.1016/j.ccr.2009.12.041.
Wu MH, Hong HC, Hong TM, Chiang WF, Jin YT, Chen YL. Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res. 2011;17(6):1306–16. doi:10.1158/1078-0432.ccr-10-1824.
Rosenthal E, McCrory A, Talbert M, Young G, Murphy-Ullrich J, Gladson C. Elevated expression of TGF-beta 1 in head and neck cancer – associated fibroblasts. Mol Carcinog. 2004;40(2):116–21. doi:10.1002/mc.20024.
Alcolea S, Anton R, Camacho M, Soler M, Alfranca A, Aviles-Jurado F-X, et al. Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE(2). J Lipid Res. 2012;53(4):630–42. doi:10.1194/jlr.M019695.
Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2012;9(1):44–54. doi:10.1038/nrgastro.2011.222.
Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol. 2010;21(1):19–25. doi:10.1016/j.semcdb.2009.10.002.
Neiva KG, Zhang ZC, Miyazawa M, Warner KA, Karl E, Nor JE. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia. 2009;11(6):583–93. doi:10.1593/neo.09266.
Kaneko T, Zhang ZC, Mantellini MG, Karl E, Zeitlin B, Verhaegen M, et al. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res. 2007;67(20):9685–93. doi:10.1158/0008-5472.can-07-1497.
Zeng QH, Li SL, Chepeha DB, Giordano TJ, Li J, Zhang HL, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8(1):13–23. doi:10.1016/j.ccr.2005.06.004.
Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest. 1997;99(11):2691–700. doi:10.1172/jci119458.
Iamaroon A, Pongsiriwet S, Jittidecharaks S, Pattanaporn K, Prapayasatok S, Wanachantararak S. Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med. 2003;32(4):195–9.
Mohtasham N, Babakoohi S, Nejad JS, Montaser-Kouhsari L, Shakeri MT, Shojaee S, et al. Mast cell density and angiogenesis in oral dysplastic epithelium and low- and high-grade oral squamous cell carcinoma. Acta Odontol Scand. 2010;68(5):300–4. doi:10.3109/00016357.2010.494622.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55. doi:10.1016/s1471-4906(02)02302-5. Pii s1471-4906(02)02302-5.
Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004;40(11):1660–7. doi:10.1016/j.ejca.2004.03.016.
Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):1155–66. doi:10.1172/jci31422.
Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011;1(4):482–97.
Togo S, Polanska UM, Horimoto Y, Orimo A. Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers (Basel). 2013;5(1):149–69. doi:10.3390/cancers5010149.
Johansson A-C, Ansell A, Jerhammar F, Lindh MB, Grenman R, Munck-Wikland E, et al. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Mol Cancer Res. 2012;10(9):1158–68. doi:10.1158/1541-7786.mcr-12-0030.
Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark). 2010;15:166–79. doi:10.2741/3613.
Leef G, Thomas SM. Molecular communication between tumor-associated fibroblasts and head and neck squamous cell carcinoma. Oral Oncol. 2013;49(5):381–6. doi:10.1016/j.oraloncology.2012.12.014.
Wheeler SE, Shi H, Lin F, Dasari S, Bednash J, Thorne S, et al. Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models. Head Neck. 2014;36(3):385–92.
Whiteside TL. Immunobiology of head and neck cancer. Cancer and Metastasis Rev. 2005;24(1):95–105. doi:10.1007/s10555-005-5050-6.
Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000;96(12):3838–46.
Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer. 2010;103(8):1245–54. doi:10.1038/sj.bjc.6605891.
Kesselring R, Thiel A, Pries R, Wollenberg B. The number of CD161 positive Th17 cells are decreased in head and neck cancer patients. Cell Immunol. 2011;269(2):74–7. doi:10.1016/j.cellimm.2011.03.026.
Costa NL, Valadares MC, Souza PPC, Mendonca EF, Oliveira JC, Silva TA, et al. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol. 2013;49(3):216–23. doi:10.1016/j.oraloncology.2012.09.012.
Dumitru CA, Gholaman H, Trellakis S, Bruderek K, Dominas N, Gu X, et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer. 2011;129(4):859–69. doi:10.1002/ijc.25991.
Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2013;228(7):1404–12. doi:10.1002/jcp.24260.
Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. 2013;62(11):1745–56. doi:10.1007/s00262-013-1476-9.
Acknowledgment
This work was supported by Ministry of Health of the Czech Republic IGA MZ NT14337-3/2013.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Raudenska, M., Gumulec, J., Fribley, A.M., Masarik, M. (2016). HNSCC Biomarkers Derived from Key Processes of Cancerogenesis. In: M. Fribley, A. (eds) Targeting Oral Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-27647-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-27647-2_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-27645-8
Online ISBN: 978-3-319-27647-2
eBook Packages: MedicineMedicine (R0)